1. In patients with pathological complete response to neoadjuvant systemic therapy, there was no tumour recurrence at 2 years 2. ...
1. Longer progression-free survival was found in patients taking trastuzumab deruxtecan compared to trastuzumab emtansine 2. Adverse events were more ...
1. Patients with refractory HER2-mutant non-small cell lung cancer (NSCLC) show clinical response to trastuzumab deruxtecan. 2. Safety profiles were ...
1. Almost 30% of patients had an objective response rate, with roughly three-quarters experiencing a reduction in tumour size. 2. ...
1. Among HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab (Herceptin), 3 year survival without invasive disease was ...
1. The addition of ramucirumab, a VEGF-2 receptor blocker, to docetaxel did not significantly increase progression free or overall survival in ...
Image: PD 1. Breast tumors with stem cell mutations in the PI3K/Akt signaling pathway had significantly higher rates of axillary ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.